Unlikely bedfellows produce cheap malaria pill
In a novel new initiative, Sanofi-Aventis, the fourth largest drugmaker in the world, teamed up with the Medicins Sans Frontières’ Drugs for Neglected Diseases Initiative to produce a cheap malaria pill. The collaboration began in 2003, and the first result, which will be available next month in 11 African countries with others around the world to follow, ...
In a novel new initiative, Sanofi-Aventis, the fourth largest drugmaker in the world, teamed up with the Medicins Sans Frontières' Drugs for Neglected Diseases Initiative to produce a cheap malaria pill. The collaboration began in 2003, and the first result, which will be available next month in 11 African countries with others around the world to follow, is a medicine called ASAQ. The drug will cost less than $1 for adults and less than 50 cents for children. ASAQ combines artesunate with an an older antimalarial drug. As FP reported last year, malaria is said to kill a child every 30 seconds. The disease kills at least 1 million people every year, mostly in sub-Saharan Africa, and simply taking cheap pills like ASAQ combined with sleeping under mosquito nets can reduce the incidence of malaria by 97 percent.
The French drugmaker will not only sell the drug at cost price to international health agencies, but is also not seeking to patent the medicine so that generic companies will be able to produce cheap versions of the drug to maximize access. This type of partnership between big "pharma" and non-profits such as MSF are rare, but will hopefully put pressure on other major companies to follow suit. Such relationships won't be easy. But as Dr. Robert Sebbag, the vice president for access to medicines at Sanofi acknowledges,
This was not a love wedding - it was a reasonable wedding... But reasonableness is often more important for a long term marriage. They've seen we are not nasty people working against poor countries and seeking only profits."
In a novel new initiative, Sanofi-Aventis, the fourth largest drugmaker in the world, teamed up with the Medicins Sans Frontières’ Drugs for Neglected Diseases Initiative to produce a cheap malaria pill. The collaboration began in 2003, and the first result, which will be available next month in 11 African countries with others around the world to follow, is a medicine called ASAQ. The drug will cost less than $1 for adults and less than 50 cents for children. ASAQ combines artesunate with an an older antimalarial drug. As FP reported last year, malaria is said to kill a child every 30 seconds. The disease kills at least 1 million people every year, mostly in sub-Saharan Africa, and simply taking cheap pills like ASAQ combined with sleeping under mosquito nets can reduce the incidence of malaria by 97 percent.
The French drugmaker will not only sell the drug at cost price to international health agencies, but is also not seeking to patent the medicine so that generic companies will be able to produce cheap versions of the drug to maximize access. This type of partnership between big “pharma” and non-profits such as MSF are rare, but will hopefully put pressure on other major companies to follow suit. Such relationships won’t be easy. But as Dr. Robert Sebbag, the vice president for access to medicines at Sanofi acknowledges,
This was not a love wedding – it was a reasonable wedding… But reasonableness is often more important for a long term marriage. They’ve seen we are not nasty people working against poor countries and seeking only profits.”
More from Foreign Policy
Lessons for the Next War
Twelve experts weigh in on how to prevent, deter, and—if necessary—fight the next conflict.
It’s High Time to Prepare for Russia’s Collapse
Not planning for the possibility of disintegration betrays a dangerous lack of imagination.
Turkey Is Sending Cold War-Era Cluster Bombs to Ukraine
The artillery-fired cluster munitions could be lethal to Russian troops—and Ukrainian civilians.
Congrats, You’re a Member of Congress. Now Listen Up.
Some brief foreign-policy advice for the newest members of the U.S. legislature.
Sign up for Morning Brief
Foreign Policy’s flagship daily newsletter with what’s coming up around the world today. Delivered weekdays.
By submitting your email, you agree to the Privacy Policy and Terms of Use and to receive email correspondence from us. You may opt out at any time.
